Skip to main content

Table 2 Hematological and non-hematological toxicities according to NCI-CTC (n = 41)

From: A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium

 

Grade 1(%)

Grade 2(%)

Grade 3(%)

Grade 4(%)

Leucocytopenia

12(29.3)

15(36.6)

6(14.6)

2(4.9)

Neutropenia

6(14.6)

14(34.1)

11(26.8)

4(9.7)

Febrile neutropenia

2(4.9)

0

0

0

Anemia

4(9.8)

16(39.0)

7(17.1)

4(9.7)

Thrombocytopenia

4(9.8)

5(12.2)

6(14.6)

4(9.7)

Nausea

15(36.6)

6(14.6)

0

0

Vomiting

7(17.1)

5(12.2)

1(2.4)

0

Diarrhea

2(4.9)

0

0

0

Increased ALT

4(9.8)

1(2.4)

0

0

Increased creatinine

4(9.8)

0

0

0

Alopecia

5(12.2)

2(4.9)

NA

NA

Neurological toxicitity

1(2.4)

0

0

0

Mucositis

2(4.9)

0

0

0

Fatigue

5(12.2)

2(4.9)

0

0

  1. ALT, alanine aminotransferase;
  2. NA, not appolicable;
  3. NCI-CTC, National Cancer Institute Toxicity Critrria